Multiple Sclerosis: References

1. Irizarry MC. Multiple Sclerosis. In: Cudkowicz ME, Irizarry MC, eds. Neurologic Disorders in Women. Boston, Ma: Butterworth–Heinemann; 1997:85.

2. Wallin MT, Page WF, Kurtzke JF. Multiple sclerosis in US veterans of the Vietnam era and later military service: race, sex, and geography. Ann Neurol. 2004;55:65–71.

3. Rosati G. The prevalence of multiple sclerosis in the world: an update. Neurological Sciences. 2001;22:117–139.

4. Van der Mei IA, Ponsonby AL, Dwyer T, et al. Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case–control study. BMJ. 2003;327:316.

5. Munger KL, Zhang SM, O'Reilly E, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology. 2004;62:60–65.

6. Franklin GM, Nelson L. Environmental risk factors in multiple sclerosis: causes, triggers, and patient autonomy. Neurology. 2003;61:1032–1034.

7. Sadovnick AD, Armstrong H, Rice GP, et al. A population–based study of multiple sclerosis in twins: update. Ann Neurol. 1993;33:281–285.

8. Ebers GC, Sadovnick AD, Dyment DA, et al. Parent–of–origin effect in multiple sclerosis: observations in half–siblings. Lancet. 2004;363:1773–1774.

9. Munger KL, Peeling RW, Hernan MA, et al. Infection with Chlamydia pneumoniae and risk of multiple sclerosis. Epidemiology. 2003;14:141–147.

10. Hernan MA, Zhang SM, Lipworth L, et al. Multiple sclerosis and age at infection with common viruses. Epidemiology. 2001;12:301–306.

11. Rutschmann OT, McCrory DC, Matchar DB. Immunization and MS: a summary of published evidence and recommendations. Neurology. 2002;59:1837–1843.

12. DeStefano F, Verstraeten T, Jackson LA, et al. Vaccinations and risk of central nervous system demyelinating diseases in adults. Arch Neurol. 2003;60:504–509.

13. Mohr DC, Hart SL, Julian L, Cox D, Pelletier D. Association between stressful life events and exacerbation in multiple sclerosis: a meta–analysis. BMJ. 2004;328:731.

14. Ackerman KD, Stover A, Heyman R, et al. 2002 Robert Ader New Investigator award. Relationship of cardiovascular reactivity, stressful life events, and multiple sclerosis disease activity. Brain Behav Immun. 2003;17:141–151.

15. Kidd D, Thorpe JW, Thompson AJ, et al. Spinal cord MRI using multi–array coils and fast spin echo. II. Findings in multiple sclerosis. Neurology. 1993;43:2632.

16. Bot JC, Barkhof F, Polman CH, et al. Spinal cord abnormalities in recently diagnosed MS patients: added value of spinal MRI examination. Neurology. 2004;62:226–233.

17. Beck RW, Trobe JD, Moke PS, et al. High– and low–risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol. 2003;121:944–949.

18. Rodriguez M, Siva A, Cross SA, et al. Optic neuritis: a population–based study in Olmsted County, Minnesota. Neurology. 1995;45:244–250.

19. Beck RW, Cleary PA, Anderson MM Jr, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med. 1992;326:581–588.

20. Beck RW, Cleary PA. Optic neuritis treatment trial. One–year follow–up results. Arch Ophthalmol. 1993;111:773–775.

21. Fischer JS, Priore RL, Jacobs LD, et al. Neuropsychological effects of interferon beta–1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. Ann Neurol. 2000;48:885–892.

22. Cantorna MT, Mahon BD. Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp Biol Med (Maywood). 2004;229:1136–1142.

23. Schwarz S, Leweling H. Multiple sclerosis and nutrition. Mult Scler. 2005;11:24–32.

24. Das UN. Is there a role for saturated and long–chain fatty acids in multiple sclerosis? Nutrition.2003;19:163–168.

25. Malosse D, Perron H, Sasco A, Seigneurin JM. Correlation between milk and dairy product consumption and multiple sclerosis prevalence: a worldwide study. Neuroepidemiology. 1992;11:304–312.

26. Ghadirian P, Jain M, Ducic S, Shatenstein B, Morisset R. Nutritional factors in the aetiology of multiple sclerosis: a case–control study in Montreal, Canada. Int J Epidemiol. 1998;27:845–852.

27. Swank RL, Grimsgaard A. Multiple sclerosis: the lipid relationship. Am J Clin Nutr. 1988;48:1387–1393.

28. Vollmer T, Key L, Durkalski V, et al. Oral simvastatin treatment in relapsing–remitting multiple sclerosis. Lancet. 2004;363:1607–1608.

29. Calder PC. n–3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr. 2006;83(suppl):1505S–1519S.

30. Besler HT, Comoglu S. Lipoprotein oxidation, plasma total antioxidant capacity and homocysteine level in patients with multiple sclerosis. Nutr Neurosci. 2003;6:189–196.

31. Paoletti R, Gotto AM Jr, Hajjar DP. Inflammation in atherosclerosis and implications for therapy. Circulation. 2004;109:III20–III26.

32. Swank RL, Goodwin J. Review of MS patient survival on a Swank low saturated fat diet. Nutrition. 2003;19:161–162.

33. Guggenmos J, Schubart AS, Ogg S, et al. Antibody cross–reactivity between myelin oligodendrocyte glycoprotein and the milk protein butyrophilin in multiple sclerosis. J Immunol. 2004;172:661–668.

34. Chan JM, Stampfer MJ, Ma J, Gann PH, Gaziano JM, Giovannucci EL. Dairy products, calcium, and prostate cancer risk in the Physicians' Health Study. Am J Clin Nutr. 2001;74:549–554.

35. Namazi MR. The beneficial and detrimental effects of linoleic acid on autoimmune disorders. Autoimmunity. 2004;37:73–75.

36. Knutson KL, Disis ML. Tumor antigen–specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother. 2005;54:721–728.

37. MacLean CH, Issa AM, Newberry SJ, et al. Effects of Omega–3 fatty acids on cognitive function with aging, dementia, and neurological diseases. Rockville, MD: Agency for Healthcare Research and Quality, US Dept of Health and Human Services; Feb 2005. AHRQ publication 05–E011–2. Evidence Report/Technology Assessment No. 114.